The allergenicity of genetically modified foods from genetically engineered crops A narrative and systematic review

INSTRUCTIONS Credit can now be obtained, free for a limited time, by reading the reviewarticle and completing all activity components. Please note the instructions listed below: Review the target audience, learning objectives and all disclosures. Complete the pre-test. Read the article and reflect on all content as to how it may be applicable to your practice. Complete the post-test/evaluation and claim credit earned. At this time, physicians will have earned up to 1.0 AMA PRA Category 1 Credit (TM). Minimum passing score on the post-test is 70%. Overall Purpose Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices. Learning Objectives At the conclusion of this activity, participants should be able to: Recognize the testing and safety features that genetically modified products are subject to in determining their allergenicity Identify the basis and rationale for genetic modification Review the evidence regarding genetically modified products and any association with food allergy Release Date: September 1, 2017 Expiration Date: August 31, 2019 Target Audience Physicians involved in providing patient care in the field of allergy/asthma/immunology Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Planning Committee Members S. Eliza Dunn, MD (Author) Jon L. Vicini, PhD (Author) Kevin C. Glenn, PhD (Author) David Fleischer, MD (Author) Matthew Greenhawt, MD, MBA, MSc (Author) Jonathan A. Bernstein, MD (CME Subcommittee) Guha Krishnaswamy, MD (CME Subcommittee) John J. Oppenheimer, MD (CME Subcommittee, Associate Editor) Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor) Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief) Disclosure Policy As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI. All identified conflicts of interest have been resolved. Disclosure of Relevant Financial Relationships: S. E. Dunn; D. M. Fleischer; K. C. Glenn; J. L. Vicini have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted. M. Greenhawt e Advisory Board for Monsanto; he received a research grant and fees; J. A. Bernstein e PI, Consultant, Speaker for AstraZeneca, CSL Behring, Novartis/Genentech, and Shire, he received research grants and fees; Speaker for Baxalta, he received fees; Consultant for Imedics, he received fees; PI and Consultant for Boehringer Ingelheim and GlaxoSmithKline, he received research grants and fees. G. Krishnaswamy e Clinical Research for CSL Behring, he received a research grant; J. Oppenheimer e Consultant for DBV Technologies, GlaxoSmithKline, and Kaleo, he received other financial gains; Clinical research for AstraZeneca, Boehringer Ingelheim, and Novartis, he received research grants. M. H. Grayson e Clinical research for Polyphor, Ltd., he received a research grant. G. D. Marshall e Clinical Research for Stallergens and Sanofi, he received research grants. Recognition of Commercial Support: This activity has not received external commercial support. Copyright Statement: Copyright (C) 2017 American College of Allergy, Asthma & Immunology. All rights reserved. CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at education@ acaai. org or 847-427-1200.